Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
30 search results for:

Diffuse large B-cell lymphoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 17-06-2018 | Lymphoma | Highlight | Teaser
    Scientific summary

    Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

    This program was made possible thanks to independent educational sponsorship from MorphoSys.

  2. 20-04-2016 | Pediatric lymphoma | Article

    Diffuse large B-cell lymphoma in children and adolescents (B mature): introduction

    Using a case-based approach, this chapter reviews the clinical characteristics of pediatric diffuse large B-cell lymphoma. Servitzoglou  MK et al. In:  PET/CT in lymphomas: a case-based atlas . Edited by Andreou JA et al. Springer International Publishing 2016. doi:10.1007/978-3-319-27380-8_21

  3. 05-12-2018 | Diffuse large B-cell lymphoma | News | Article

    Durable response to tisagenlecleucel shown in DLBCL

    Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

    Published in:
    N Engl J Med 2018; doi:10.1056/NEJMoa1804980 ASH 2018; San Diego, California, USA; 1–4 December
  4. 07-09-2018 | Diffuse large B-cell lymphoma | News | Article

    Circulating tumor DNA predicts DLBCL outcomes

    Pretreatment levels of circulating tumor DNA, as well as changes during therapy, are independently prognostic of outcomes in patients with diffuse large B-cell lymphoma and can add to established risk factors, findings indicate.

    Published in:
    J Clin Oncol 2018; doi:10.1200/JCO.2018.78.5246
  5. 21-05-2018 | Diffuse large B-cell lymphoma | News | Article

    First-line rituximab plus GemOx promising in older patients with DLBCL

    The combination of rituximab, gemcitabine, and oxaliplatin has potential for the treatment of older patients with a new diagnosis of diffuse large B-cell lymphoma, suggests a Chinese phase II trial.

    Published in:
    Lancet Haematol 2018; Advance online publication
  6. 04-05-2017 | Diffuse large B-cell lymphoma | News | Article

    Lenalidomide maintenance delays disease progression in DLBCL

    Lenalidomide maintenance therapy significantly improves progression-free survival in elderly patients with diffuse large B-cell lymphoma who respond to first-line chemotherapy, phase III trial data show.

    Published in:
    J Clin Oncol 2017; Advance online publication
  7. 15-05-2018 | FDA | News | Article
    approvalsWatch

    Tisagenlecleucel approved for relapsed, refractory DLBCL

    Read more on this CAR T-cell therapy announcement here

  8. 22-12-2017 | B-cell lymphoma | News | Article

    CAR T-cell therapy effective for refractory large B-cell lymphomas

    The results of two studies published in The New England Journal of Medicine support the use of autologous chimeric antigen receptor T cells directed against CD19 in patients with relapsed or refractory B-cell lymphomas.

    Published in:
    N Engl J Med 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA
  9. 19-10-2017 | CAR T-cell immunotherapy | News | Article
    approvalsWatch

    Second CAR T-cell therapy receives FDA approval

    Read more on this decision affecting treatment of some types of large B-cell lymphoma here

  10. 02-03-2018 | Hematologic cancers | News | Article

    Next-generation PI3Kδ inhibitor umbralisib warrants further investigation

    By comparison, the objective response rate was 31% among the 13 patients with diffuse large B-cell lymphoma, but the researchers note that other PI3Kδ inhibitors have not been reported to be active in this group of patients.

    Published in:
    Lancet Oncol 2018; Advance online publication
  11. 21-04-2017 | Lymphoma | Feature | Article

    Lymphoma in practice: Professor Anas Younes speaks to medwireNews

    Professor Anas Younes tells  medwireNews about the current issues in lymphoma practice, both for the clinician and patients.

  12. 01-08-2016 | Lymphoma | Article

    Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine

    An expert summary of the diagnostic and prognostic value of biomarkers related to alterations in the most common types of lymphoma at the genetic, epigenetic, protein, and tumor microenvironment levels. Mod Pathol  2016; 29: 1118–1142. doi:10.1038/modpathol.2016.92

    Author:
    Ruifang Sun, L Jeffrey Medeiros, Ken H Young
  13. 07-07-2017 | FDA | News | Article
    approvalsWatch

    Rituximab–hyaluronidase human combination approved for multiple indications

    medwireNews : The FDA has granted regular approval for combined use of subcutaneous rituximab and hyaluronidase human for follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

  14. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    Richter’s transformation Transformation to an aggressive large cell B-cell lymphoma variety from CLL is called Richter’s transformation and this can occur in <10% cases.

    Author:
    Tanya Siddiqi, Steven T Rosen
  15. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    In this review, Younes et al describe the most promising agents in clinical development for the treatment of lymphoma and provide expert opinion on new strategies that may streamline drug development. Nat Rev Clin Oncol  2017; 14: 335–346. doi:10.1038/nrclinonc.2016.205

    Author:
    Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Frank Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
  16. 09-03-2017 | Lymphoma | Case report | Article

    CNS lymphoma

    Histologically, most PCNSL cases are classified as high grade B-cell lymphomas and are usually indistinguishable from diffuse large B-cell lymphoma (DLBCL) although other morphologies including low-grade lymphoma and T-cell lymphomas have been reported as well [6,7].

    Author:
    Matthew Mei
  17. 13-04-2017 | Lymphoma | Article

    Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma

    Ribi K, Rondeau S, Hitz F et al. Support Care Cancer 2017. doi:10.1007/s00520-017-3698-4

  18. 28-09-2016 | Hematologic cancers | Book chapter | Article

    Staging

    In:  Handbook of Lymphoma . Edited by Younes A. Springer International Publishing, 2016. doi:10.1007/978-3-319-08467-1_4

    Author:
    Colette Owens, Anas Younes
  19. 16-09-2016 | Hematologic cancers | Book chapter | Article

    Risk factors, etiology, and pathogenesis

    In this chapter, the authors review current knowledge of the risk factors for and molecular  pathogenesis of the most common lymphomas. In:  Handbook of Lymphoma . Edited by Younes A. Springer International Publishing, 2016. doi:10.1007/978-3-319-08467-1_2

    Author:
    Anastasios Stathis, Colette Owens
  20. 02-03-2017 | Liquid biopsy | Review | Article

    Integrating liquid biopsies into the management of cancer

    The power of NGS analysis of ctDNA in disease surveillance has been evaluated in a retrospective analysis 150 in 107 patients with diffuse large-B-cell lymphoma (DLBCL) who had achieved complete remission with the EPOCH regimen (comprising etoposide, prednisone, vincristine cyclophosphamide and doxorubicin) in any of three different trials that used EPOCH as a control treatment.

    Author:
    Giulia Siravegna, Silvia Marsoni, Salvatore Siena, Alberto Bardelli

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.